Biomarkers - Resources

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

Events

In-Person & Online Events

Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.

Online Activities

Our Monthly Science Exchanges and Webinars keep you connected to the conversation.

All Online Activities
Community

Speakers

Attracting leading experts & the brightest minds in the industry to educate, inform and excite our attendees.

More Info

Sponsors

Our range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

More Info

Media Partners

We work with leading journal publications on reciprocal marketing arrangements.

More Info
Services

In-Person Services

At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.

More Info

Digital Marketing Services

Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.

More Info
Resources

Browse All Resources

The latest in biomarkers research, from development and diagnostics to precision medicine.

All Biomarkers Resources

Latest Resources

Imaging Starts Using Brand New Radiotracer from Nuclidium

21/10/24 - The radiotracer is the first part of Nuclidium’s proposed ‘theranostic pipeline’ which aims to diagnose, stage, and then treat prostate cancer.

01/10/24 - GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease

06/09/24 - Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
Contact
Our Brands

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

Oxford Global

Precision Medicine

Discovery & Development

NextGen Biomed

A New Golden Age for Target Identification: Accessing the Novel Druggable Space with Discovery Proteomics

On-demand webinar presented by Mo Jain, MD, PhD, Founder and CEO, Sapient and Jonathan Usuka, PhD, MBA Chief Business Officer, Sapient

Watch Now

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.

Read Now

Content Type

Categories

Keywords

Diagnostic Development

Imaging Starts Using Brand New Radiotracer from Nuclidium

The radiotracer is the first part of Nuclidium’s proposed ‘theranostic pipeline’ which aims to diagnose, stage, and then treat prostate cancer.

Diagnostic Development

GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease

GHR’s total investment in C2N has now broken $50 million since 2020.

Biomarker Analysis

Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality

The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.

Personalised Medicine

Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy

SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.

Biomarker Discovery & Development

Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma

The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.

Liquid Biopsies

Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions

Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.

Personalised Medicine

Life Science Players Join €23m European Project for Precision Medicine, PRECISEU

The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.

Liquid Biopsies

Feinstein Institutes Links Blood Biomarkers to Psychosis in Alzheimer's Patients

The global aging population means that rates of Alzheimer's disease are expected to reach 14 million patients by 2060, many of whom will experience psychosis.

Genomic Biomarkers

ZERO Precision Medicine Programme Reports Outstanding Efficacy in High-Risk Paediatric Cancers

The first-of-its-kind trial presents a positive outlook for cancer types with historically poor survival rates.

Genomic Biomarkers

Hope for New Prognostic Biomarkers & Therapeutic Options From Tumour Metabolism-Targeting Breast Cancer Study

Understanding the interplay between the tumour microenvironment and immunometabolic states could unlock a wealth of therapeutic targets and biomarkers.

Diagnostic Development

New Zika-Specific Synthetic Biomarker Can Differentiate From Dengue Virus

A test that identifies Zika distinct from dengue could make a definite impact to expectant mothers and reproductive-age women that are at risk from the mosquito-borne disease.

Diagnostic Development

Blood Test for Alzheimer's Granted Breakthrough Device Status by FDA

A blood test for the phosphorylated protein pTau-217 could be a critical step towards early diagnosis and screening of Alzheimer's disease.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Next